"病院 医療 入院 外来"

During the past decade, Sekino Hospital conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 7 clinical trials were completed, i.e. on average, 63.6% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 7 clinical trials were completed. i.e. 140% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sekino Hospital" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Sekino Hospital" are "COVID-19" (2 trials), "Heart Failure" (2 trials), "Asthma" (1 trials), "Atopic Dermatitis" (1 trials) and "Clostridium Difficile Infection" (1 trials). Many other conditions were trialed in "Sekino Hospital" in a lesser frequency.

Most popular intervention types in "Sekino Hospital" are "Drug" (10 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Empagliflozin" (2 trials), "PF-07321332" (2 trials), "Ritonavir" (2 trials) and "Baloxavir Marboxil" (1 trials). Other intervention names were less common.

The vast majority of trials in "Sekino Hospital" are 12 trials for "All" genders.

Currently, there are NaN active trials in "Sekino Hospital". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Sekino Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Sekino Hospital, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".